Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 507 | 114 | 339 |
| Samples | 210 | 81 | 111 |
| Peptides | 194 | 66 | 82 |
Function
CYFIP1 · Cytoplasmic FMR1 interacting protein 1
This gene encodes a protein that regulates cytoskeletal dynamics and protein translation. The encoded protein is a component of the WAVE regulatory complex (WRC), which promotes actin polymerization. This protein also interacts with the synaptic functional regulator FMR1 protein and translation initiation factor 4E to inhibit protein translation. A large chromosomal deletion including this gene is associated with increased risk of schizophrenia and epilepsy in human patients. Reduced expression of this gene has been observed in various human cancers and the encoded protein may inhibit tumor invasion. [provided by RefSeq, Mar 2022].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 188 amino-acid changes on canonical ENST00000617928 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CYFIP1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CYFIP1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 11/612 2% |
| Hodgkins Lymphoma | 0/16 0% | 2/122 2% |
| Gastric Carcinoma | 3/74 4% | 16/1809 1% |
| Melanoma | 4/210 2% | 17/1899 1% |
| Colorectal Carcinoma | 13/143 9% | 20/3239 1% |
| Adrenocortical Carcinoma | 1/3 33% | 0/112 0% |
| Neuroendocrine Tumour | 3/154 2% | 3/577 1% |
| Other Solid Cancers | 5/94 5% | 6/1515 0% |
| Bladder Carcinoma | 1/58 2% | 5/956 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 5/1390 0% |
| Head and Neck Carcinoma | 4/85 5% | 4/1574 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Thyroid Gland Carcinoma | 4/45 9% | 2/1592 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 3/810 0% |
| B-Cell Non-Hodgkins Lymphoma | 5/88 6% | 3/2534 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Neuroblastoma | 4/87 5% | 0/1331 0% |
| Other Sarcomas | 1/69 1% | 1/699 0% |
| Breast Carcinoma | 2/144 1% | 7/3264 0% |
| Hepatocellular Carcinoma | 1/46 2% | 4/2210 0% |
| Ovarian Carcinoma | 0/109 0% | 2/998 0% |
| Glioma | 1/52 2% | 3/2127 0% |
| B-Lymphoblastic Leukemia | 2/55 4% | 2/2640 0% |
Mutation Distribution
Where CYFIP1 is mutated · all tissues, split by cell line vs tissue
How many mutations in CYFIP1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 507 mutations in CYFIP1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|